Real-world Secukinumab Outcomes in Canadian HS Patients (NCT07282015)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
2. Adult patients at the time of informed consent signature.
3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
5. Patients who can understand written and spoken Canadian English or French.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (15 Sites)

• Novartis Investigative Site — Calgary, Alberta
• Novartis Investigative Site — Calgary, Alberta
• Novartis Investigative Site — Winnipeg, Manitoba
• Novartis Investigative Site — Fredericton, New Brunswick
• Novartis Investigative Site — St. John's, Newfoundland and Labrador
• Novartis Investigative Site — Cobourg, Ontario
• Novartis Investigative Site — Hamilton, Ontario
• Novartis Investigative Site — London, Ontario
• Novartis Investigative Site — Markham, Ontario
• Novartis Investigative Site — Mississauga, Ontario
• Novartis Investigative Site — Richmond Hill, Ontario
• Novartis Investigative Site — Toronto, Ontario
• Novartis Investigative Site — Saint-Jérôme, Quebec
• Novartis Investigative Site — Sherbrooke, Quebec
• Novartis Investigative Site — Saskatoon, Saskatchewan

📞 Contact the Study Coordinator

Phone: +41613241111

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Phoenix, Arizona
• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa — Phoenix, Arizona
• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
• Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa. — Birmingham, Alabama
• Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository — San Francisco, California

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.